Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumor × Crizotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 43 Lung Neoplasms 10 Neoplasms 6 Lymphoma, Large-Cell, Anaplastic 6 Neoplasm Metastasis 5 Multiple Myeloma 4 Lymphoma 4 Granuloma, Plasma Cell 4 Adenocarcinoma 4 Neuroblastoma 3 Colorectal Neoplasms 3 Uveal Melanoma 2 Recurrence 2 Hematologic Neoplasms 2 Glioblastoma 2 Carcinoma, Squamous Cell 2 Carcinoma, Renal Cell 2 Carcinoma 2 ALK-positive NSCLC 2 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Sarcoma, Clear Cell 1 Sarcoma, Alveolar Soft Part 1 Rhabdomyosarcoma, Alveolar 1 Relapsed Pediatric Solid Tumor 1 Rare Tumor 1 Multiple Endocrine Neoplasia Type 2a 1 Melanoma 1 Lymphoma, Non-Hodgkin 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡